SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is drawing attention after a strong quarterly report and rapid growth in its AI-compute business prompted bullish reactions and analyst upgrades. Traders are weighing that growth against heavy capital spending and an upcoming share unlock, while a possible Tesla merger remains speculative.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix sold off after its earnings update despite a profit beat, as softer revenue and margin guidance and a reduced advertising outlook raised concerns about slowing growth and ad execution. Traders are divided between viewing the decline as an overreaction and expecting further weakness amid competition and content concerns.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders position around the anticipated 80th-event milestone and final survival analysis for its Phase 3 REGAL trial of GPS in AML; the companys last disclosed count was 78 events. Bulls interpret the extended wait as potentially encouraging and speculate about a squeeze or buyout, while skeptics stress that neither the milestone nor favorable results have been confirmed.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary fiscal first-quarter update sharply raised its revenue outlook and gross-margin guidance, citing stronger AI-platform demand, driving a sharp after-hours rally. Many traders welcomed the figures and anticipated short covering, while others questioned whether margins, cash flow and execution can sustain the improvement and whether the stock can hold its gains.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets weak, range-bound trading and upcoming earnings are focusing attention on whether cloud and AI growth can justify heavy infrastructure spending. Traders are split between viewing the pullback as a buying opportunity and worrying about capex, competition, and poor price action; quantum-computing news also draws interest but has not clearly shifted the debate.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs planned acquisition of low-band spectrum to expand Starlink Mobile has driven concerns about future competition, weighing on AT&T alongside other major carriers. Traders are split between seeing a lasting threat to wireless pricing and viewing the selloff as an overreaction given the years of investment and infrastructure needed to compete; many are buying the dip for AT&Ts fiber business and dividend.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias AI-RAN call on T-Mobiles live commercial network, alongside its NVIDIA partnership and a planned SoftBank trial, is fueling interest in its push into AI infrastructure. Traders are weighing that progress against whether AI and cloud orders can translate into revenue and profits, with earnings seen as a key test amid recent share-price weakness.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings are the main focus, with traders debating whether strong Cloud and AI demand can justify heavy AI infrastructure spending and deliver returns. Some expect results or Gemini developments to lift the shares, while others worry about rising capex and continued weakness near resistance.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention centers on TG Therapeutics MS conference data, especially preliminary azer-cel Phase 1 findings in progressive MS that traders describe as showing disability improvements and encouraging safety in a small cohort. The reaction is optimistic but tempered by the early, limited evidence, with investors also watching long-term BRIUMVI outcomes and switching data.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Oppenheimers upgrade of Zoom to Outperform, citing uptake of its AI platform and its shift toward broader communications and workflow services, is drawing attention. Some traders see the upgrade as validation of Zooms growth story, while others remain skeptical about its growth prospects and focus on speculative Anthropic-related upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally

Equity

Adial on Thursday announced that it has bought privately held Azora Therapeutics.

Adial Pharmaceuticals Applies For FDA Priority Voucher Program For AD04

(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL) on Monday said it has submitted its AD04 application for consideration under the U.S. Food and Drug Administration Commissioner's National Priority Voucher Pilot Program (CNPV...

Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder

Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.read more...

Why Did Adial Pharmaceuticals Stock Plunge Over 20% After Hours Today?

The reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule.

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring

Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.

Adial Pharmaceuticals Inc

Registration filing

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

Bullish Sentiment

<ul class="summary-bullets"><li>The main goal of the deal is to bring Azora’s lead drug candidate, called AT177, into Adial’s pipeline.</li><li>Adial expects to begin the first human clinical trial for the experimental drug in mid-2027.</li><li>The firm is also raising up to $64 million in total through private financing as part of the deal.</li></ul>Shares of Adial Pharmaceuticals, Inc. (ADIL) jumped as much as 110% after the company announced the acquisition of privately held Azora Therapeutics, Inc., a biopharmaceutical company developing treatments for inflammatory diseases, in a transaction accompanied by up to $64 million in gross proceeds from a concurrent private placement financing.The stock is now on track for its best day since September 2020, if gains hold.The main goal of the deal is to bring Azora’s lead drug candidate, called AT177, into Adial’s pipeline. AT177 is an experimental once-daily pill designed to treat ulcerative colitis by working directly in the colon to reduce inflammation, while limiting effects on the rest of the body.The drug is currently in the final stages of lab and animal testing needed before it can be tested in humans. Adial expects to begin the first human clinical trial in mid-2027.The transaction marks a shift for Adial, which focuses on addiction treatments.<h2 class="st-heading-2">Terms Of The Deal</h2>Under the deal, Azora’s shareholders will receive Adial stock. After the transaction closes, former Azora shareholders will own about 51% of the combined company, current Adial shareholders about 8%, and new investors putting money into the financing about 41%. The deal has already been approved by both companies’ boards and by Azora’s shareholders. Adial will still need approval from its own shareholders for certain parts of the deal, which it plans to seek soon.Adial is also raising up to $64 million in total through private financing as part of the deal. Approximately $32 million will be invested immediately, while the remaining $32 million will be released once the company successfully begins its first human clinical trial of AT177. Proceeds will be used primarily to fund development of AT177 and initiate early-stage clinical studies, the company said.<h2 class="st-heading-2">How Did ADIL Retail Traders React?</h2>On Stocktwits, retail sentiment around ADIL stock jumped from ‘neutral’ to ‘bearish’ over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user termed the news “perfect” and expressed optimism for the stock rallying on Friday as well.<stembedurl>https://www.stocktwits.com/AtillaB/message/656149262</stembedurl>Another, however, expressed doubts about the deal.<stembedurl>https://www.stocktwits.com/fastmoneytraders/message/656149353</stembedurl>According to data from Koyfin, both analysts covering ADIL rate it ‘Buy’ or higher. The stock has a 12-month average price target of $25, which represents a potential upside of over 1000% from the stock’s last close.<a href="https://stocktwits.com/symbol/ADIL">ADIL stock</a> has fallen 39% over the year.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ttd-stock-in-spotlight-after-firm-ropes-in-zendesk-marketing-chief-retail-hopes-new-hires-turn-things-around-at-trade-desk/cZKTDdaR728">TTD Stock In Spotlight After Firm Ropes In Zendesk Marketing Chief – Retail Hopes New Hires Turn Things Around At Trade Desk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Adial Pharmaceuticals logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$ADIL Amateurs—what else is there to say? For a year and a half, Carry kept spouting nonsense about Phase 3 for AD04 launching in December 2025, yet he was unable to move the project forward at all. It looks like he just used shareholders' money to fund a long vacation before finally packing his bags and leaving.

Patrik

$ADIL You come in as an investor and entrust your money to the company for the drug AD04—based on Carry’s boast a year and a half ago that they would begin Phase 3 at the end of 2025 (he’s a liar)—only for him to now just tuck the drug away in a drawer right before Phase 3. If he’s truly this incompetent, I don’t understand how he managed to stay in leadership for so long. And, of course, his salary is completely out of proportion to the size of a company that doesn’t even have an approved drug.

$ADIL A fucking company full of incompetent idiots. These moronic shares are designed solely for moronic speculators. Carry is a total loser who hasn’t done a single thing—absolutely nothing—in a year and a half. Sure, he got some drugs manufactured—fine. But at the pace he’s moving, by the time he actually gets anything done, those drugs will be fit for the trash because they’ll have expired.

$ADIL granted a new employee stock option award of 155,446 shares as an inducement under Nasdaq Rule 5635(c)(4).

Feed

News

Sentiment

Fundamentals

Info

ADIL Adial Pharmaceuticals Inc

Fundamentals

Latest ADIL News